Non-interventional study on the efficiency of Erbitux in the first-line therapy in patients with metastatic colorectal cancer with wild-type KRAS gene

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jul 2021 Results of subgroup analyses from EREBUS, ERBITAG and CEBIFOX assessing overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer APEC presented at the 23rd World Congress on Gastrointestinal Cancer
28 Sep 2016 According to the Merck KGaA media release, the company will present data from this trial at the ESMO 2016.
11 Apr 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com